Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes
But A Comeback Remains Possible
Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.
You may also be interested in...
More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.
KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.